Generic allergy relief drugs advair aerolate allegra benadryl bricanyl claritin d decadron dramamine periactin phenergan proventil serevent singulair ventolin zyrtec exelon sumycin diflucan sporanox elimite vermox eskalith haldol lamictal lithobid mellaril prolixin risperdal achromycin amoxyl bactrim biaxin ceclor ceftin ciloxan cipro duricef floxin garamycin keftab levaquin noroxin spectrobid trimox vibramycin zithromax anafranil celexa effexor xr elavil luvox pamelor paxil prozac sinequan tofranil wellbutrin zoloft buspar arava cataflam feldene imuran indocin sr mobic naprelan relafen zyloprim alesse ortho tri cyclen triphasil ditropan leukeran aceon adalat atacand avapro calan capoten cardizem cardura cilexetil combipres cordarone coreg coumadin cozaar diovan esidrix hydrodiuril hytrin hyzaar imdur ismo isoptin isordil lanoxin lasix lisinopril lopressor lotensin lozol minipress moduretic monoket norpace norvasc persantine plavix plendil pletal prinivil prinzide procardia rocaltrol sorbitrate tenoretic ticlid trental vaseretic vasodilan vasotec zebeta zestril lipitor lopid mevacor pravachol zocor actos amaryl avandia diamicron glucophage glucophage sr glucotrol glucotrol xl glucovance micronase prandin precose starlix aldactone microzide oretic dilantin neurontin aciphex bentyl colace cytotec detrol imodium nexium pepcid ac max strength prevacid prilosec protonix reglan zantac zofran propecia proscar combivir epivir retrovir viramune zerit cycrin danocrine deltasone levothroid prednisone provera synthroid altace inderal tenormin vastarel aralen flagyl grisactin myambutol cialis levitra viagra viagra gel viagra soft tabs antivert flexeril flextra ds robaxin soma zanaflex betagan evista fosamax mestinon sandimmune advil anacin celebrex esgic plus fioricet imitrex medipren panadol ponstel pyridium tylenol ultram eldepryl tegretol condylox rebetol zovirax atarax cleocin differin kenalog nizoral retin a synalar temovate ambien zyban compazine meridia aygestin clomid motrin naprosyn nolvadex parlodel serophene generic temovate, clobetasol propionate online price compare generic temovate clobetasol propionate ; buy online temovate, clobetasol propionate is a topical anti-inflammatory medication that helps reduce itching, redness, and swelling associated with many skin conditions.

Can't keep my eyes from the circling sky, tongue-tied and twisted just an earthbound misfit, i status: offline 02 10 04 quote by: michaelberrier can someone give me the fortune cookie version of why it' s not ok to use cardizem with atrial fib flutter but it is ok use it for svt.

Risks that could cause actual results to differ include the possibility that our existing and the new drug candidates may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the fda in a timely manner or at all, the possibility that the fda may not accept our future anda filings, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs and therefore may not be successfully commercialized, the possibility that price and other competitive pressures may make the marketing and sale of our generic drugs not commercially feasible, the possibility that our efforts to acquire or in-license and develop additional oncology drug candidates may fail, our limited marketing experience, our limited experience with the generic drug industry, our dependence on third parties for clinical trials and other risks that are described in further detail in the company's reports filed with the securities and exchange commission. These medicines will cure yeast, trichomonas and bacterial vaginosis. ; Take 2 medicines: 1 medicine from Box 1, and also the medicine in Box 2, for instance, cardizem 360 mg. Cases Related to Hatch-Waxman, Other Collusion Cases . Hatch-Waxman Amendments: A Brief Summary . Brand Name Generic Name Ativan Tranxene lorazepam clorazepate dipostassium . BuSpar buspirone . Carcizem CD diltiazem . Cipro ciprofloxacin hydrochloride . Hytrin terazosin hydrochloride . K-Dur-20 potassium chloride . Neurontin gabapentin . Nolvadex tamoxifen citrate . Paxil paroxetine . Prilosec omeprazole . Procardia XL extended-release nifedipine . Relafen nabumetome . Taxol paclitaxel . Tiazac diltiazem hydrochloride . Cases Related to Fraud Involving Pricing . Lupron Depot leuprolide . Cases Related to Deceptive Marketing . Claritin loratadine . Coumadin warfarin sodium . Premarin conjugated estrogens . Synthroid levothyroxine . understanding of the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act1 is necessary in order to appreciate the tactics pharmaceutical companies use to delay and prevent generic competition. A more complete discussion of Hatch-Waxman and the drug approval process is covered in a companion piece, "Overview of Hatch-Waxman: Legislative Background." Congress enacted Hatch-Waxman in 1984 in part to facilitate the development and expedite the approval of generic drugs. Hatch-Waxman shortened the generic drug approval process by allowing generic manufacturers to file an Abbreviated New Drug Application "ANDA" ; , incorporating data that the brand-name drug manufacturer has already submitted to the FDA. With the ANDA, the generic manufacturer must make one of four certifications to the FDA regarding each patent the brand-name manufacturer has submitted to the Orange Book.2 The Orange Book is a publication that lists all prescription drugs approved for use in the U.S. and the patents covering those drugs. The fourth of these certifications, referred to as a Paragraph IV Certification, is the one that has been manipulated by drug manufacturers to extend brand-name monopolies. With a Paragraph IV Certification, the generic manufacturer claims that the brand drug patent is invalid or will not be infringed by the generic.3 When a generic manufacturer files a Paragraph IV Certification, it must notify the patent holder for simplicity, referred to here as the brand-name drug manufacturer ; . If the brand-name drug manufacturer sues the generic manufacturer for patent infringement within 45 days of notice, the FDA cannot issue final approval of the generic, or any other generics related to that brand-name drug, for 30 months the "30-Month Stay" ; unless the patent expires or there is resolution of the lawsuit. The first generic manufacturer filing an ANDA with a Paragraph IV certification is eligible for 180 days during which its product will be the only generic on the market the "Exclusivity Period" ; . The Exclusivity Period starts to run either when the generic is commercially marketed or when there is a court decision finding that the patent is either invalid or not infringed by the generic.4 Despite the goal of Hatch-Waxman to expand consumer access to generics, the 30-Month Stay and the Exclusivity Period have presented crafty brand-name manufacturers with opportunities to extend their monopolies through a variety of anticompetitive tactics. 30-Month Stay: Since the filing of a patent infringement action within 45 days of notice of a Paragraph IV Certification ANDA delays FDA approval of the generic, brand-name manufacturers have an incentive to claim, obtain, and list as many patents as possible. Even a completely frivolous patent infringement action will preclude FDA approval for up to 30 months. This has resulted in brand-name manufacturers "warehousing" as many patents as they can and filing frivolous lawsuits when notified of a Paragraph IV Certification ANDA. Exclusivity Period: The Exclusivity Period is important because the first ANDA filer with a Paragraph IV certification--the generic manufacturer entitled to 180 days exclusivity--may control the timing of the product's introduction. As a result, it can determine when the brand-name monopoly ends.5 FDA final approval does not require commercial marketing. The first ANDA filer is permitted to delay marketing as long as it likes, but the FDA cannot grant final approval to any other generic until the first ANDA filer gets its 180 days.6 Creative--but potentially illegal-- partnerships between the first ANDA filer and the brand-name drug manufacturer can effectively prevent generic competition for the brand-name drug for an indefinite period. The profits flowing from the brand-name manufacturer's continued monopoly are sometimes shared with the first ANDA filer in exchange for agreeing not to go to market.7.

Commissioners: Attached you will find the original staff review and Resolution Number 01-148 "Resolution to Amend the Agreement for the Community Mental Health Board of Clinton-Eaton-Ingham Counties" that authorizes an amendment to the Agreement for the Community Mental Health Board of Clinton-Eaton-Ingham Counties by amending the formula by which the participating counties are represented on the Community Mental Health Board according to Census data. The Board of Commissioners approved this resolution in May of this year and the agreements implementing this amendment have been prepared for signature; however, according to the authorizing legislation Mental Health Code and Urban Cooperation Act of 1967 ; each participating entity must hold a public hearing prior to the amendment taking effect. The July 23 Human Services meeting will serve as Ingham County's public hearing and Clinton and Eaton Counties will establish their own public hearings in order to implement the amendment. If you should have any questions, please contact me and cardura.

Table - dosing and costs of the calcium channel blockers drug initial dose usual dosage range cost * x 30 days verapamil 80 mg tid 80 - 160 mg tid regular isoptin, generic ; 180 mg daily 120 mg daily - 240 mg bid long acting isoptin sr ; 180 mg daily 120 - 480 mg daily - verelan ; diltiazem 30 mg tid 30 mg tid - 90 mg qid regular cardizem, generic ; 60 mg bid 60 - 180 mg bid - 31 * - long acting cardizem sr ; * 120 mg daily 120 -300 mg daily - cardizem cd ; 5 mg daily 5 - 20 mg daily - felodipine plendil , renedil ; nifedipine 10 mg tid 10 mg tid - 30 mg qid regular capsules adalat, generic ; 10 mg bid 10 - 40 mg bid - 72 * - long acting adalat pa ; * 30 mg daily 30 - 120 mg daily - 72 adalat xl ; 5 mg daily 5 - 10 mg daily - amlodipine norvasc ; 20 mg tid 20 - 40 mg tid - 58 nicardipine cardene ; * based upon wholesale acquisition cost feb. Name patent is invalid. Brand name manufacturer automatically sues the generic drug manufacturer for patent infringement to delay the generic drug's entry for thirty months, regardless of the suit's merit. Brand name manufacturer will spend money on the suit, but will continue to earn monopoly profits on its drug. 2 ; Then the brand name manufacturer "settles" the infringement litigation by agreeing to pay the generic manufacturer a portion of its monopoly profits in exchange for the generic's agreement to stay off the market. 3 ; Recent examples of cases involving allegations of such anticompetitive patent settlements include: a ; FTC consent decree with Abbott Laboratories and Geneva Pharmaceuticals regarding Hytrin, a hypertension drug worth $542 million per year. Abbott allegedly paid Geneva $4.5 million; Geneva agreed not to enter the market with any generic version of Hytrin for a specified period, and agreed not to assign its 180 day exclusive marketing period to another generic, blocking generic entry. See Complaint, In the Matter of Abbott Laboratories, FTC Docket No. C-3945 May 22, 2000 Complaint, In the Matter of Geneva Pharmaceuticals, Inc., FTC Docket No. C-3946 May 22, 2000 ; . The FTC complaint, order, analysis to aid public comment and other materials relating to the Hytrin settlement are available at : ftc.gov os 2000 05 index #26. b ; FTC complaint and final consent order against Hoechst Marion Roussel and Andrx Corp. regarding Cardixem CD, a hypertension drug worth $700 million per year. Hoechst paid Andrx over $80 million and delayed Andrx's generic entry for over a year. FTC complaint filed May 2000; final consent order issued May 2001. ; See Decision and Order, In the Matter of Hoechst Marion Roussel, Inc. et al., FTC Docket No. 9293 May 11, 2001 ; , available at : ftc.gov opa 2001 05 fyi0130 ; Agreements, Decision and Order, and Analysis, In the Matter of Hoechst Marion Roussel, Inc., FTC Docket No. 9293 April 2, 2001 ; , available at ftc.gov opa 2001 04 hoechst ; c ; FTC complaint and settlement involving ScheringPlough Corp., Upsher-Smith Labs, and American Home Products relating to K-Dur, a potassium chloride supplement worth $220 million per year. Schering paid first-ANDA filer Upsher $60 million and licensed several products of minimal value in exchange for Upsher's agreement to delay selling its or any other ; generic version of K-Dur. Somewhat similar terms with AHP. The FTC recently settled its complaint with AHP. See and carisoprodol.
How to use cardizem: cardizem may be taken with or without food.
A cholesterol-lowering medication called cholestyramine questran ; has also demonstrated some effectiveness and ceftin. Instructed to take all of the pills, regardless of when symptoms resolve. Explain that this will ensure that all bacteria are destroyed, and that the growth of resistant strains will not be encouraged. Patients should be discouraged from saving unused antibiotics for use at a later date.
Biovail launched cardizeem la, a once-daily oral graded-release diltiazem formulation used in the treatment of hypertension, in the united states on april 2, 200 ca4dizem la belongs to the family of medications called calcium channel blockers and cefzil.

Drug Name Diflucan Fluconazole ; fluconazole generic equivalent ; diflunisal generic ; Digitek Digoxin Lanoxin in Canada ; Digoxin Lanoxin in Canada ; Dihydroergotamine NS Mesylate ; Dilantin Phenytoin ; Dilaudid diltiazem generic ; diltiazem generic ; diltiazem SR generic ; diltiazem SR generic ; Cardizej CD Diltiazem CD ; diltiazem CD generic equivalent ; Ca5dizem CD Diltiazem CD ; diltiazem CD generic equivalent ; Carrdizem CD Diltiazem CD ; diltiazem CD generic equivalent ; Cardizem CD Diltiazem CD ; diltiazem CD generic equivalent ; Diovan Valsartan ; Diovan Valsartan ; Diovan HCT Valsartan HCTZ ; Diovan HCT Valsartan HCTZ ; Diovan HCT Valsartan HCTZ ; Dipentum Olsalazine ; Diprolene Cream Betamethasone Dipropionate ; Diprolene Ointment Betamethasone Dipropionate ; Diprolene Lotion Betamethasone Dipropionate ; dipyridamole generic ; dipyridamole generic ; dipyridamole generic ; Ditropan oxybutynin generic equivalent ; Ditropan XL Oxybutynin XL ; Ditropan XL Oxybutynin XL ; divalproex generic ; divalproex generic ; divalproex generic ; docusate calcium generic ; docusate sodium generic ; domperidone generic ; Dostinex Carbergoline ; Dovonex Cream Calcipotriol ; Dovonex Ointment Calcipotriol ; Dovonex Lotion Calcipotriol ; Cardura doxazosin ; doxazosin generic equivalent ; Cardura doxazosin ; doxazosin generic equivalent ; Cardura doxazosin ; doxazosin generic equivalent ; doxepin generic ; Strength 150 mg 150 mg 500 mg 0.125 mg 0.25 mg 4 mg mL -- 30 mg 60 mg 90 mg 120 mg 120 mg 120 mg 180 mg 180 mg 240 mg 240 mg 300 mg 300 mg 80 mg 160 mg 80 12.5 mg 160 12.5 mg 160 25 mg 250 mg 0.05% mg 50 mg 75 mg 5 mg 5 mg 5 mg 10 mg 125 mg 250 mg 500 mg 240 mg 100 mg 10 mg 0.5 mg 0.005% mg 1 mg 2 mg 2 mg 4 mg 4 mg 10 mg Quantity 1 100 Price $13.80 $11.74 $46.38 Not available $53.50 $53.57 $31.36 Not available Not available $22.62 $43.69 $59.57 $65.01 $104.53 $66.71 $188.37 $92.74 $192.05 $124.81 $230.84 $161.35 $32.66 $37.32 $31.99 $38.02 Not available $59.12 $50.85 $38.07 $13.27 $27.34 $36.19 Not available - see below $23.85 $185.24 $185.42 $43.07 $44.15 $73.27 $5.24 $9.18 $96.38 $139.22 $58.94 $57.46 Not available - see below $52.25 $77.48 $56.42 $90.52 $58.85 $15.74 10. Diltiazem HCl Cardizem 60mg 240mg caps Diltiazem HCl Accupril 5mg - 30 tabs Afeditab CR 60mg Cardizem CD 300mg caps Accuretic 10-12.5mg - 30 Cardizem LA Diltiazem HCl tabs Altace 10mg 240mg 360mg caps Accuretic 20-12.5mg - 30 Cardizem LA tabs Altace 5mg 300mg Diovan Accuretic 20-25mg - 30 Cardizem LA tabs Amiodarone 360mg Diovan HCT Acebutolol 400mg - 30 Cardizem LA Disopyramide caps Atacand 420mg Phosphate Accupril 40mg - 30 tabs Adalat CC Aceon 2mg - 30 tabs Afeditab CR 30mg - 30 tabs Altace 1.25mg - 30 caps Altace 2.5mg - 30 caps Benazepril 10mg - 30 tabs Benazepril 20mg - 30 tabs Benazepril 40mg - 30 tabs Atacand HCT Avalide Avapro Benicar Benicar HCT Betapace Cardizem SR Cartia XT 240mg Cartia XT 300mg Catapres Catapres-TTS Cordarone Coreg Corgard Corzide Covera-HS Cozaar Dynacirc Dynacirc CR Enduronyl Epipen Ethmozine Flecainide Acetate Guanabenz Acetate 8mg Hytrin Hyzaar Imdur Inderal 40mg and celebrex. If you have trouble getting to the pharmacy, have financial concerns, or have other problems that make it difficult for you to get your medicines, let your doctor know, for instance, cardize cd 360. The results of this clinical trial were favourable and we expect to file the supplemental nda for cardizem® la in mid-200 in addition, we have completed, or are in the process of completing, a number of comparative phase iv studies involving cardizem® la and celexa.

Great buy cheap cardizem rpsgb, been tested andin fact blue and white.
Page 125 ; studies of the drugs used to treat attention deficit hyperactivity disorder adhd ; illustrates how misleading it can be to draw conclusions about the cause of a disorder from a treatment just because it may be effective in ameliorating symptoms and cephalexin.

These three US patterns were rareobserved in the same cyst. When this did happen, a decrease in size was the most frequent first sign of mely sponse to the drugs 11 of 17 cysts. Cardizem LA generated revenues of $59.7 million in 2005, compared with $53.6 million in the full year of 2004. Further to our May 2005 alliance with Kos, Biovail now manufactures and supplies Cardizem LA to Kos at contractually determined prices that are in excess of 30% of their net selling prices. The Teveten line, divested to Kos, generated revenues of $6.4 million in 2005, compared with $17.6 million in 2004. Biovail no longer has an economic interest in Teveten. For the 12 months ended December 31, 2005, Biovail's legacy products generated revenues of $133.4 million, compared with $121.6 million in 2004, an increase of 10%. This performance was largely attributable to a reduction in wholesaler inventory levels in 2004. Partially offsetting factors include the expected year-over-year declines in total prescription volumes for these mature products. Product revenue in 2005 for Biovail's portfolio of generic products was $135.2 million, compared with $149.7 million in the prior year, a decrease of 10%. Total prescription volume for these products increased 1% in 2005. MORE REGULATORY, PRODUCT-DEVELOPMENT MILESTONES In 2005, Biovail's product-development activities continued to focus on medicines that targeted unmet patient needs in primary-care markets. The Company also remained steadfast in its efforts to identify ways to increase exclusivity periods and or strengthen intellectual property protection, thereby extending the commercial life and value of the products it develops. The year 2005 will be long remembered by Biovail as one of the Company's most prolific in terms of its regulatory successes. Biovail received six product approvals, including one tentative approval. The Company received approval from the U.S. Food and Drug Administration FDA ; for a once-daily formulation of tramadol, indicated for the treatment of moderate to moderately severe chronic pain; an orally disintegrating tablet ODT ; formulation of tramadol for the treatment of moderate to moderately severe pain; extendedrelease GlumetzaTM, developed in partnership with Depomed, Inc., for the treatment of Type II diabetes; and for its orally disintegrating tablet formulation of citalopram for the treatment of depression in adults. Biovail received approval from the Therapeutic Products Directorate Canada TPD ; for GlumetzaTM, which it launched in late November. Tentative FDA approval was received for an orally disintegrating tablet formulation of zolpidem and cipro. Treatments both treatment and control groups received standard medical therapy; treatment group also received omt 2 visits week, duration of care not mentioned. Vital Sign Remarks: The patient entered the study on 20-Jun-95 with a baseline weight of 166.0 lbs. At week 20, the weight had increased to 179.0 lbs. increase 7% ; , which was considered to be of potential clinical concern. Adverse events of moderately severe weight gain and increased appetite had been reported by the investigator on day 114, and were considered related to study medication. The patient withdrew from the study on day 182 due to lack of efficacy. At week 24, the weight was 180.5 lbs and claritin and cardizem, for example, cardizem cd 360 mg.

Cardizem dosage

294 pages paperback, ISBN 13: 3-933344-13-1 englisch ISBN 13: 978-3-933344-13-7 englisch Hardly any other name in the 1950s caused such excitement as that of Bruno Grning. Hardly any event called forth such opposing reactions as those surrounding Bruno Grning. From some he was loved and respected, from others hated and fought against. For some he was the last hope after a path of no success through the various instances of medical science. For others he posed a great danger, for those whose carefully and over centuries built up picture of the world was threatened with collapse. What was Bruno Grning for a human being that he sparked such strong emotions? Some knelt down before him, others drew the sword. With hardly any other person of his time did the praise of "Hosanna" and the curse of "Crucify him!" lay so close to each other. Bruno Grning: A phenomenon worth looking into. The clinician doing the evaluation will consider a variety of alternative diagnoses, such as a mood disorder, a medical problem or a toxic substance and climara. Attorneys general of all 50 states, puerto rico and the district of columbia filed suit claiming that a conspiracy to inflate the price on generic versions of cardizem® caused consumers to pay millions of dollars more than they should have for the drug. Gastrointestinal: anorexia, constipation, diarrhea, dry mouth, dysgeusia, dyspepsia, mild elevations of sgot, sgpt, ldh, and alkaline phosphatase see warnings, cardizem cd capsules, acute hepatic injury ; , thirst, vomiting, weight increase.

Cardizem children

Site email save cardizem - drugdigest compare cardizem to similar drugs.

FUNGUS INFECTION? RECURRENT BOILS LESIONS SKIN INFECTIONS ; ALLERGIC TO INSECT BITE BEE STING ; ? MEDICATION ALLERGIC TO MEDICATION S ; ? NAME ? OTHER ALLERGIES? PLEASE LIST BELOW. BONE FRACTURE? WHEN? WHERE? JOINT DISLOCATION? WHEN? WHERE? FOOT PROBLEMS? SHOULDER INJURY? BACK INJURY OR FREQUENT BACKACHES? HIP INJURY OR CONSTANT HIP PAIN? KNEE INJURY SPRAIN LIGAMENT TEAR ; ? RECURRENT KNEE PAIN? OSGOOD SCHLATTERS CHONDROMALACIA ANKLE INJURY? FRACTURE BROKEN NOSE? OTHER JOINT PROBLEMS? JOINT? BONE INFECTION?, for example, cardizem la generic. Tramtormauon by cytochrome P-45O mixed function oxidase. Coadmlnlstration ol CARDIZEM wtth other agents which toBow the same route ol btotranstormation may result In the compstittve Mibltion of metabolism Dosages of simBariy metabolized drugs, partlcularty those ot low therapeutic njtio or In petients with renal and or hepatic impairment may require adjustment CAMZBI when starting or stopping ccnconttsntly mii * Btsnxl to maintain optimum therapeutic blood levels. Bef-tloettn: ControBed and uncontrolleddomestic studies suggest that concomitant use ot CARDIZEM $nd beta-blockers or AgltaUs Is usually weB tolerated AvaMabk data art not sufficient, however, to predict the effects of concomitant treetment parttcutarty In petients wtth left ventricular dysfunction or cardiac conduction abnormalities. Administration ol CARDIZEM diltiazem hytlrochloride ; concomltantty with proprenotol In ftvt normal volunteers resulted In increased propranolol levels In aU subjects and bioevaUabBlty of propranolol was increased approximattty50%. If combination therapy Is Initiated or withdrawn In conjunction wtth propranolol, an adjustment In the propranolol dose may be warranted. See WARNINGS. ; CfciMOUbr A study In six healthy volunteers has shown a significant increase In peak oWazem plasma levels 50% ; and ana-under-mnarve 53% ; after a one-week course of dmetktkie at 1X0 mg per day and diltiazem SO mg per day. Ranltidtne produced smaier, nonsignificant Increases. The effect may be mediated by dmeMne's known lnhB ; ltlon of hapatk cytocfrome P O, the enzyme system probably responsibb lor the first-pass metabolism ol oUtiizem. Patients currently receiving dUtianm therapy should be carefully monitored for a change m pharmacological effect when Initiating and discontinuing therapy with dmetkHne. An adjustment In the diltiazem dose may be warranted. W H t Administration ot CARDIZEM witi&goxln in 24 healttry male subjects Increased plasma dk oxln concentrations approximately 20%. Another investigator found no increase In dtfoxln levels In 12 patients wtth coronary artery disease. Since there have been conflicting results regarding tie effect ol dlgoxtn leyts.lt Is recommended that dboxln levels be monitored when Initiating, adjusting, and discontinuing CARDIZEM therapy to avoid possible over- or under-digltaliatlon See WARmGS and cardura.

Cardizem lyo-ject syringe cardizem lyo-ject syringe, after reconstitution contains a clear, colorless, sterile, nonpyrogenic solution.

© 2006-2007 Buy-online.atspace.biz -All Rights Reserved.